z-logo
open-access-imgOpen Access
Efficacy of Rapid Treatment Initiation Following Primary Toxoplasma gondii Infection During Pregnancy
Author(s) -
Andrea Hotop,
Harald Hlobil,
Uwe Groß
Publication year - 2012
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cis234
Subject(s) - spiramycin , medicine , sulfadiazine , toxoplasmosis , folinic acid , pregnancy , toxoplasma gondii , fetus , pyrimethamine , obstetrics , adverse effect , immunology , malaria , chemotherapy , antibiotics , plasmodium falciparum , fluorouracil , genetics , erythromycin , antibody , microbiology and biotechnology , biology
Treatment of Toxoplasma gondii infection acquired during pregnancy differs in many countries. In Germany, spiramycin is given until the 16th week of pregnancy, followed by at least 4 weeks of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infection stage of the fetus. If infection of the fetus is confirmed by polymerase chain reaction or if fetal ultrasound indicates severe symptoms (hydrocephalus, ventricular dilation), treatment is continued until delivery with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal blood and observation of possible adverse effects. In other European countries, such as France, only spiramycin is given unless infection of the fetus is proven.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom